https://www.selleckchem.com/products/byl719.html
We additionally provide insight into the therapeutic implications of targeting these interactions, particularly in the context of cancer immunotherapy.The most common bone disease in humans is osteoporosis (OP). Current therapeutics targeting OP have several negative side effects. Bone morphogenetic protein 2 (BMP2) is a potent growth factor that is known to activate both osteoblasts and osteoclasts. It completes these actions through both SMAD-dependent and SMAD-independent signaling. A novel interaction between the BMP type Ia receptor
Like
Comment
Share
